zoledronic acid (aclasta)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Avascular Necrosis of Femoral Head
Conditions
Avascular Necrosis of Femoral Head
Trial Timeline
Jul 1, 2009 → Jun 1, 2012
NCT ID
NCT00939900About zoledronic acid (aclasta)
zoledronic acid (aclasta) is a phase 3 stage product being developed by Novartis for Avascular Necrosis of Femoral Head. The current trial status is completed. This product is registered under clinical trial identifier NCT00939900. Target conditions include Avascular Necrosis of Femoral Head.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00939900 | Phase 3 | Completed |
Competing Products
4 competing products in Avascular Necrosis of Femoral Head
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KW-3357 | Kyowa Kirin | Phase 3 | 77 |
| KW-3357 | Kyowa Kirin | Phase 3 | 77 |
| KW-3357 + Plasma-derived antithrombin | Kyowa Kirin | Phase 3 | 77 |
| BAY 3389934 + Matching Placebo / Diluent | Bayer | Phase 1 | 30 |